載入...
Which Leber congenital amaurosis patients are eligible for gene therapy trials?
BACKGROUND: In 2007, clinical trials began for gene-replacement therapy for RPE65-associated Leber congenital amaurosis (LCA). To enroll, subjects must have both disease-causing RPE65 alleles identified. Determining which patients have true disease-causing mutations requires a multistep approach. ME...
Na minha lista:
| Main Authors: | , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2009
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2860791/ https://ncbi.nlm.nih.gov/pubmed/19840725 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaapos.2009.08.006 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|